Jazz Pharmaceuticals (JAZZ) Q1 Earnings and Revenues Lag Estimates

Jazz, which belongs to the Zacks Medical - Biomedical and Genetics industry, posted revenues of $897.84 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 8.52$901.98 million. The company has topped consensus revenue estimates three times over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commen ...